register

News & Trends - Pharmaceuticals

Fresenius Kabi gains TGA approval for new biosimilar

Health Industry Hub | June 29, 2020 |

Pharma News: Fresenius Kabi secured TGA registration of Idacio, a biosimilar medicine to AbbVie’s Humira (adalimumab).

With global sales of US$20 billion in 2018, AbbVie’s Humira has been a target for a number of biosimilars.

The drug is an antibody treatment for a range of inflammatory conditions, including various forms of arthritis, inflammatory bowel disease and psoriasis.

Fresenius Kabi’s Idacio (adalimumab rch) is approved for:

  • Rheumatoid arthritis as monotherapy or in combination with methotrexate
  • Juvenile idiopathic arthritis – in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis
  • Psoriatic arthritis – moderate to severe disease
  • Ankylosing spondylitis
  • Crohn’s disease in adults and children (≥ 6 years)
  • Ulcerative colitis – moderate to severe disease
  • Psoriasis in adults and children – active moderate to severe hidradenitis suppuratives (acne inversa)
  • Uveitis – non-infectious intermediate, posterior and pan-uveitis

Other adalimumab biosimilars registered in Australia include Amgen’s Amgevita since 2017, Samsung Bioepis’ Hadlima since 2018 and Sandoz’s Hyrimoz since 2019.


News & Trends - MedTech & Diagnostics

Labor's one-off funding a band aid for public hospitals while private sector left in limbo

Labor’s one-off funding a band aid for public hospitals while private sector left in limbo

Health Industry Hub | February 6, 2025 |

The Federal Government has committed a one-off funding boost of $1.7 billion to public hospitals under a one-year extension to […]

More


News & Trends - Pharmaceuticals

AI-powered test to reshape use of hormone therapy in prostate cancer

AI-powered test to reshape use of hormone therapy in prostate cancer

Health Industry Hub | February 6, 2025 |

Australian researchers are pioneering the use of artificial intelligence (AI) to enhance decision-making in prostate cancer treatment, specifically focusing on […]

More


News & Trends - MedTech & Diagnostics

Vantive debuts as standalone business amid complex landscape of chronic kidney disease

Vantive debuts as standalone business amid complex landscape of chronic kidney disease

Health Industry Hub | February 6, 2025 |

Vantive, formerly Baxter’s Kidney Care business, has officially launched as a standalone company. The move follows Baxter’s completion of the […]

More


News & Trends - MedTech & Diagnostics

Optalert unveils test for sleep apnoea as Philips expands partnership in pharmacy program

Optalert unveils test for sleep apnoea as Philips expands partnership in pharmacy program

Health Industry Hub | February 6, 2025 |

An Australian medical technology company has introduced a test designed to identify obstructive sleep apnoea (OSA), broadening access to sleep […]

More


This content is copyright protected. Please subscribe to gain access.